Related Experiment Video

Updated: Jan 29, 2026

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
07:46

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

34.0K

Inhaled medications in cystic fibrosis beyond antibiotics

Angela Sepe1,2, Valeria R Villella3, Chiara Cimbalo1,2

  • 1Department of Translational Medical Sciences, University Federico II, Naples, Italy.

Minerva Pediatrica
|February 15, 2019
PubMed

Insights

Inhaled hypertonic saline and dornase alfa offer early intervention for cystic fibrosis (CF) lung disease. These treatments improve airway clearance and reduce exacerbations by rehydrating airways and breaking down DNA, addressing obstruction, inflammation, and infection.

Area of Science:

  • Pediatric Pulmonology
  • Respiratory Medicine
  • Pharmacology

Background:

  • Cystic Fibrosis (CF) lung disease begins in early infancy.
  • Early intervention is crucial for managing CF pulmonary disease.
  • Inhaled medications are a key strategy for early CF treatment.

Purpose of the Study:

  • To review the clinical impact of inhaled solutions in pediatric cystic fibrosis.
  • To summarize evidence supporting inhaled hypertonic saline and dornase alfa in CF.
  • To highlight the role of these therapies in addressing the CF lung disease cycle.

Main Methods:

  • Literature review of studies on inhaled hypertonic saline and dornase alfa in CF.
  • Analysis of papers focusing on early intervention strategies for CF lung disease.
  • Synthesis of data on the mechanisms and effects of these inhaled solutions.

Main Results:

  • Inhaled hypertonic saline enhances airway surface liquid rehydration.
  • Dornase alfa facilitates extracellular DNA cleavage in CF airways.
  • Both treatments improve mucociliary clearance and reduce pulmonary exacerbations.
  • Indirect anti-inflammatory effects contribute to managing CF lung disease.

Conclusions:

  • Inhaled hypertonic saline and dornase alfa are effective early interventions for CF lung disease.
  • These therapies target airway obstruction, inflammation, and infection in CF.
  • Evidence supports the clinical impact of these inhaled solutions in improving CF outcomes.

More Related Videos

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

7.6K
Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

1.8K

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
786
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
868
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
520
Antibiotic Selection00:57

Antibiotic Selection

Overview
59.9K
Pulmonary Ventilation: Inhalation01:24

Pulmonary Ventilation: Inhalation

Pulmonary ventilation is a vital process that ensures the exchange of oxygen and carbon dioxide in the lungs. It refers to the movement of air into and out of the lungs, enabling the body to obtain oxygen and remove waste carbon dioxide. In this article, we will explore the intricacies of pulmonary ventilation, including its underlying principles, mechanisms, and the interplay of pressures within the respiratory system.
Boyle's law becomes particularly pertinent when examining respiratory...
8.0K
Inhalational Anesthetics: Overview01:20

Inhalational Anesthetics: Overview

Inhalation anesthetics are drugs that induce general anesthesia upon inhalation. They work by increasing the sensitivity of GABAA receptors or inhibiting NMDA receptors, leading to a decrease in central nervous system activity. The depth of anesthesia can be rapidly adjusted by changing the concentration of the inhaled gas. Some common examples of inhalational anesthetics include volatile liquids like isoflurane, desflurane, sevoflurane and gases like xenon and nitrous oxide. Isoflurane, a...
1.1K